Literature DB >> 18321907

Dramatic functional improvement following bariatric surgery in a patient with pulmonary arterial hypertension and morbid obesity.

Michael A Mathier1, Joan Zhang, Ramesh C Ramanathan.   

Abstract

Pulmonary arterial hypertension (PAH) and morbid obesity both dramatically impair functional capacity. New therapies have emerged for both conditions, including pharmaceutical agents for the former and bariatric surgery for the latter. The presence of both conditions simultaneously, however, may limit the applicability and effectiveness of these therapies. We report a case of a morbidly obese patient with severe PAH and functional impairment. A three-drug combination regimen consisting of oral bosentan and sildenafil, and inhaled iloprost produced sufficient hemodynamic improvement to allow for the performance of bariatric surgery. Over the subsequent 7 months, body weight, oxygen requirement, functional class, and 6-min walk distance all improved dramatically despite the persistence of PAH. While such surgery is typically denied to patients with PAH, we suggest that aggressive medical therapy for patients with PAH may allow for its safe performance, and that the clinical improvement resulting from the subsequent weight loss may be quite dramatic.

Entities:  

Mesh:

Year:  2008        PMID: 18321907     DOI: 10.1378/chest.07-0815

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Improvement in severe pulmonary hypertension in obese patients after laparoscopic gastric bypass or sleeve gastrectomy.

Authors:  Eric G Sheu; Richard Channick; Denise W Gee
Journal:  Surg Endosc       Date:  2015-06-20       Impact factor: 4.584

Review 2.  Bile acids and bariatric surgery.

Authors:  Vance L Albaugh; Babak Banan; Hana Ajouz; Naji N Abumrad; Charles R Flynn
Journal:  Mol Aspects Med       Date:  2017-04-17

Review 3.  Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension.

Authors:  Bradley A Maron; Jane A Leopold; Anna R Hemnes
Journal:  Br J Pharmacol       Date:  2020-02-18       Impact factor: 8.739

4.  Calorie Restriction Attenuates Monocrotaline-induced Pulmonary Arterial Hypertension in Rats.

Authors:  Mingge Ding; Jingyi Lei; Yinxian Qu; Huan Zhang; Weichuan Xin; Feng Ma; Shuwen Liu; Zhichao Li; Faguang Jin; Enqing Fu
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

5.  Pulmonary Arterial Hypertension and Insulin Resistance.

Authors:  Elisa A Bradley; David Bradley
Journal:  J Mol Genet Med       Date:  2014-01-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.